ConsumerLab.com uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.

About ConsumerLab.com

Posted March 23, 2019

BLUEFUSION Capsules for Sexual Enhancement Recalled

On March 21, 2019, Ata Int. Inc. issued a recall of its BLUEFUSION capsules, which are promoted for sexual enhancement, because FDA analysis found them to contain sildenafil, tadalafil, desmethyl carbodenafil, dithiodesmethyl carbodenafil, scutellarin and daidzein.

Sildenafil, the active ingredient in the prescription drug Viagra, and tadalafil, the active ingredient in Cialis, are prescribed for erectile dysfunction. These drugs can cause symptoms like headache and flushing, and can interact with medications containing nitrates such as nitroglycerine, resulting in dangerously low blood pressure. Desmethyl carbodenafil and dithiodesmethyl carbodenafil are similar to sildenafil and tadalafil, and can have similar effects and side effects.

Daidzein is a phytoestrogen, and scutellarin is a herbal flavonoid.

Recalled BLUEFUSION capsules were distributed nationwide in the U.S. between January 2015 and March 2019 to retail stores and through the internet. They are packaged in 1-count blister packs and can be identified by UPC code 7.48252. 66460.0. All lots within expiry are being recalled.

Consumers who have purchased this supplement should stop using and discard it. Consumers and healthcare providers can report any adverse reactions to the FDA's MedWatch Voluntary Reporting Program.

(See ConsumerLab.com's Review of Sexual Enhancement Supplements for tests of related products.)

See related warnings:

FDA Warns Consumers Not to Use Certain Sexual Enhancement Supplements

Sexual Enhancement Supplement Found to Contain Prescription Drug

Sexual Enhancement Supplements Contain Prescription Drugs

Sexual Enhancement Supplements for Men and Women Recalled

To see the complete recall, use the link below.